Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis

Background: TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Research design and methods: Herein, we performed a meta-analysis aimed to evaluate any gr...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Gennaro Gadaleta-Caldarola, Laura Lanotte, Stefania Infusino, Arianna Gadaleta-Caldarola, Francesca Matilde Schipilliti, Claudia Citrigno, Cataldo Petrarota, Antonio Cusmai, Alessandro Rizzo
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2023-01-01
Serier:	Cancer Treatment and Research Communications
Fag:	Breast cancer Triple-negative breast cancer Antibody drug conjugates Datopotamab deruxtecan Dato-Dxd
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2468294223000977
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!